Board of Directors
Elmar Schnee brings a wealth of experience from the international pharmaceutical industry, having held senior leadership and Board positions at a number of global pharmaceutical products and services companies.
Elmar most recently served on the Board of Jazz Pharmaceuticals. He also serves as a Non-Executive Director on listed Santhera AG and Calliditas AB and several private companies. Prior to this his global career spanned a range of senior roles at companies including Merck KGaA, as General Partner and member of the Executive Board, and Merck Serono as CEO.
In addition to Santhera and Calliditas, Elmar Schnee also serves as a director of Genkyotex SA (a subsidiary of Calliditas) alongside private companies Moleac Pte, Moleac RX Pte, Noorik AG, Damian Pharma AG, Kuste Biopharma, Mindmaze, Genpharm, GenKyoTex Suisse SA, ProCom RX Holding SA and MyDIO SA.
The Board has undertaken a thorough review of each of Elmar’s external appointments and is satisfied that he has sufficient time to meet all of his Board responsibilities at Clinigen. Further, the Board finds the additional insight gained by his participation on other Boards to be of enormous benefit.
Shaun has been the CEO of Clinigen since November 2016 and has the responsibility for the Group achieving its KPIs and plays a central role in setting the Group strategy. Shaun has played a pivotal role in the development of Clinigen, joining the Company in January 2012 as Chief Operating Officer, when it was a privately-owned company with a turnover of £82m.
He was a key part of the executive team that took Clinigen through IPO in September 2012 and has been a fundamental part of the leadership of the impressive strategic growth of the Company.
Prior to joining Clinigen, Shaun held senior global strategic, commercial and operational roles at Pfizer, Sanofi, Wolters Kluwer Health and the KnowledgePoint360 Group (now part of UDG Healthcare).
Shaun is currently Chairman of C7 Health Limited, a provider of software and services for the healthcare sector.
The Board is satisfied that this external appointment does not impact upon the CEO’s ability to discharge his role at the Company effectively.
Ian has spent his business career in life science and was founder and CEO of Biotrace International PLC, which was a listed company until its sale to 3M in December 2006.
Prior to these appointments Ian was a non-executive Director of Ergomed PLC and Executive Chairman of Bioquell PLC, non-executive Chairman of Quantum Pharma PLC, Cyprotex PLC and Celsis Group Ltd. He has also served on the boards of various other public and private companies including Aim listed companies; Evans Analytical Group and AOI Medical Inc.
Ian studied at Cardiff University obtaining a B.Sc. and M.Sc. in Microbiology. He is a Chartered Biologist, a Fellow of the Royal Society of Biology and a member of the Institute of Directors.
In addition to his current role as Executive Chairman of Circassia Group PLC, Ian is also currently non-executive Chairman of Redcentric PLC.
Anne has a strong track record within the biopharma sector, bringing with her over 25 years of financial experience with both public and private companies.
Anne is a Chartered Accountant (FCA), and corporate tax adviser (CTA – AITI) and holds a degree in Business Studies from Trinity College, Dublin. Anne’s previous roles include CFO of BBI Diagnostics Group Limited and FTSE-listed Vectura Group plc. Prior to her role at Vectura, Anne held a number of senior finance positions at Celltech Group plc, Medeva plc and KPMG.
Anne is CFO of Kymab Ltd, a biopharmaceutical company acquired by Sanofi in April 2021 for an upfront payment of $1.1 billion and up to $350 million in deferred consideration. She is also a Non-Executive Director of Elementis plc, a global specialty chemicals company.
Professor Boyd has accumulated over 30 years of extensive medical and policy experience within the pharmaceutical sector, holding senior roles within some of the world’s largest pharmaceutical companies.
He began his pharmaceutical career with Glaxo Group Research Limited. From 1988, he led ICI’s cardiovascular medical research team, and later assumed the role of Director of Clinical and Medical Affairs at ICI Pharma, Canada.
In 1999, after four years as Head of Medical Research for Zeneca Pharmaceuticals, he became Director of Research and Development for Ark Therapeutics Limited where he was responsible for delivering the majority of key development milestones.
In 2005, Professor Boyd left to set up Alan Boyd Consultants Limited, to focus on aiding and supporting early stage life-science based companies in Europe, North America and Japan.
Professor Boyd is Clinigen's designated Non-Executive Director for workforce engagement.
Professor Boyd is currently CEO of Alan Boyd Consultants Limited, a private specialist biopharmaceutical consultancy company. He is also a Director of BaxterBoyd Limited and Celentyx Limited.
Ian has over 25 years of international experience in management and transactions within the life sciences sector.
He is currently an Operating Partner of London-based Advent Life Sciences LLP. Ian previously spent eight years as CEO of the privately held antifungal drug development company F2G Limited and before that CEO of the oncology R&D company, Chroma Therapeutics Limited. Prior to that he was Senior Vice President, Business Development at UK biotechnology company Celltech Group plc. Ian has worked extensively in licensing, M&A and market development in the UK, Europe and the US and holds a BSc (Hons.) from University College London and an MBA from Boston University. He holds Board positions at Clinigen Group plc and is Chairman of Bioventix plc.
Sharon is an experienced non-executive board director as well as having proven top-level experience in leading high impact global marketing, commercialisation and growth strategies for world class pharmaceutical corporations.
Sharon has held numerous senior operational and strategic roles at Eli Lilly, Abbott and most recently as VP, Global Marketing and Commercial Operations at AbbVie US [2012-2017] leading their global specialty franchise and development of commercial and launch capabilities. She has a M.Sc. in Business Administration from Trinity College, Dublin and a B.Sc. in Biotechnology from Dublin City University. She has a Chartered Director Program Diploma from the Institute of Directors.
Sharon is currently a Non-Executive Director for Circassia Group plc where she is Chair of the Remuneration Committee. She is also on the Board of MorphoSys AG (Audit & Risk Committee).
Amanda trained and qualified as a UK solicitor at Freshfields Bruckhaus Deringer and has over 20 years of legal and governance experience.
Before joining Clinigen in June 2017, she was Vice President and European General Counsel at Shire Pharmaceuticals Group plc where she had spent 14 years in positions of increasing responsibility in the UK and US. She began her professional career as a commodity trader for Cargill.